论文部分内容阅读
促红素(EPO)应用于临床后,对改善尿毒症贫血取得了显著效果,但国内外均有报道EPO治疗过程中有高血压的现象,并成为应用EPO治疗早期停药的最主要原因,目前,这类报道极少有涉及对照组的临床观察。本文通过对27例高剂量促红素EPO(9000U/W)治疗组、20例低剂量(4500U/W)治疗组、及20例未用EPO的对照组进行为期一个月的动脉血压监测和临床观察,结果发现,各组之间血压升高率无统计学差异,认为治疗剂量范围内的EPO在用药后一个月内对血压无明显影响,其对血压的影响只是个别现象,且多是一过性的,但不排除一个月以后的影响。
Erythropoietin (EPO) has been applied clinically to improve uremic anemia and achieved a significant effect. However, there are reports of hypertension in EPO both at home and abroad and become the main reason for the early withdrawal of EPO. At present, few reports of this type involve the clinical observation of the control group. The aim of this study was to evaluate the one-month arterial blood pressure monitoring in 27 high-dose erythropoietin EPO (9000U / W) and 20 low-dose (4500U / W) and 20 control subjects without EPO Observation, the results showed no significant difference in the rate of increase in blood pressure among the groups that EPO within the therapeutic dose within one month after treatment had no significant effect on blood pressure, and its impact on blood pressure is only an individual phenomenon, and mostly one Too transient, but does not rule out the impact of a month later.